Twenty twenty, that was a plenty. Of everything.
11 January 2021
Well yes, what a year it was, in joy and sorrow, something to be remembered. While earlier these New Year blogs, written by yours truly, have been more or less a retrospective view of what we achieved and how much we grew, now it feels these typical business topics are only minor things of the past year.Read more
Metabolite identification and profiling – what is it?
1 December 2020
When scientists are developing new drugs, it is important to pay attention also to the drug biotransformation products forming in the body (i.e. metabolites) for a number of reasons. This blog post aims to elucidate what metabolite identification (metID) and profiling is about.Read more
Glycoprofiling of antibodies – what, how and why?
15 October 2020
Proteins go through various post-translational modifications (PTM) while produced by the cells. Glycosylation is one of the most common PTM and it can have tremendous effects on the physicochemical properties, structure, and function of proteins. Failures in the physiological glycosylation process can lead to serious health conditions, which describes its importance. This blog post elucidates why it is crucial to know and characterise glycoprofile of glycoprotein-based biologics and how this can be done.Read more
Optical tools for studying biomolecular interactions
19 August 2020
Understanding binding specificity, affinity and kinetics is essential information when developing biological drugs. Surface plasmon resonance (SPR) and biolayer interferometry (BLI) are optical techniques used for investigating biomolecular interactions.Read more
Meet the team: Part 1
18 June 2020
We’ve been writing this blog for four years now and gone over some very interesting topics regarding ADME and explained the importance of many of the research services we offer to support companies in drug discovery and development. Rarely though, have we introduced the people behind those services but now we’ll change that. It’s time to meet the team!Read more
